Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma

The purpose of this research study is to see how metformin, when used in combination with standard of care (SOC) treatment for metastatic (cancer that has spread) soft tissue sarcoma can improve patient outcomes.

Trial Details

NCT ID
NCT07291297
Phase
PHASE2
Sponsor
Wake Forest University Health Sciences
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Metformin Hydrochloride ER
Locations (sample)
  • Charlotte, North Carolina, United States|35.22709,-80.84313
  • Winston-Salem, North Carolina, United States|36.09986,-80.24422

Key Eligibility Criteria

  • Advanced unresectable or metastatic/intermediate/high grade soft tissue sarcoma
  • Age ≥ 18 years at the time of enrollment
  • Initiating first line systemic therapy for advanced/metastatic disease (treatment naïve for advanced/metastatic disease)
  • Participants who have not yet initiated first line systemic therapy: expected to initiate front-line therapy within 4 weeks of initiating metformin

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →